NR ATNL
AU Murdoch,H.; Desmond,L.; McLuckie,G.; Sutton,J.M.; Raven,N.D.H.
TI Development of an Ultra-sensitive Assay for the Detection of CJD in Blood Donations
QU International Conference - Prion 2005: Between fundamentals and society's needs - 19.10.-21.10.2005, Congress Center Düsseldorf - Poster Session: Human prions, risk of blood products, and therapy HUMAN-09
PT Konferenz-Poster
AB
Currently, there is no reliable clinical test for CJD and the most likely risk to public health comes from onward transmission of CJD agents by iatrogenic means. Recent evidence indicates that vCJD is transmissible by blood transfusion. This possibility raises concerns about the safety of blood and plasma products. Measures brought in to reduce the risk have had a negative impact on blood stocks in the UK. Therefore, there is an urgent need for a sensitive test for both detection of disease in blood donations and diagnosis of patients. The development of a reliable, validated screening method for blood donations would have a significant value in reducing the risks of iatrogenic transmission by blood transfusion and/or surgery and increase blood stocks by enabling the removal of donor exclusion categories currently in place in the UK. We are also investigating the assay for the detection of the CJD agent on surgical instruments and its use for the validation of surgical instrument cleaning and decontamination.
A novel ultra-sensitive immunoassay has been developed at Health Protection Agency, Porton Down based on the properties of a thermostable adenylate kinase (AK) marker label. The assay has been used to assess detection of spiked recombinant prion protein (recPrP) in whole blood and sera using the commercially available anti-prion monoclonal antibody, 6H4 (Prionics) labelled with AK. The results demonstrate that recPrP can be detected at levels in the femtogram range. The project is now focussed on the further development of the assay to look at detection of BSE 301V infected material spiked into blood and sera. This will be compared to murine blood from terminally infected animals to define the detection limits of the assay in blood and enable validation of the assay by comparison with existing bioassay data. The ultimate goal will be to be transfer and evaluate the assay using human blood samples.
IN Mit einem optimierten Immunoassay unter Verwendung der thermostabilen Adenylatkinase zur Markierung erreichen die Autoren von der Health Protection Agency in Porton Down eine auch für Bluttests ausreichende Nachweisgrenze im Femtogrammbreich.
AD H.Murdoch, L.Desmond, G.McLuckie, J.M.Sutton, N.D.H.Raven, Health Protection Agency - Porton Down, UK
SP englisch
PO Deutschland